ADVFN - Advanced Financial Network.
HOME» AMEX » P » PTN Stock Price » PTN Stock News

Palatin Share News

 Palatin Technologies, Stock Price
PTN Stock Price
 Palatin Technologies, Stock Chart
PTN Stock Chart
 Palatin Technologies, Stock News
PTN Stock News
 Palatin Technologies, Company Information
PTN Company Information
 Palatin Technologies, Stock Trades
PTN Stock Trades

Palatin, AstraZeneca Obesity Drug Trial Halted on Adverse Event

By Kristin Jones Palatin Technologies Inc. (PTN) said a clinical trial for an obesity drug under development as part of a collaboration with AstraZeneca PLC (AZN, AZN.LN) has been halted after a man enrolled in the study became ill. The safety review committee of AstraZeneca PLC (AZN), which was conducting the trial, halted the Phase 1 trial of AZD2820 after a serious adverse event was reported. The affected subject, who may have suffered an allergic reaction after his first dose, was treated at the site and has fully recovered. A review and investigation of the incident has begun. "We are pleased that the subject has fully recovered from this unfortunate adverse event and we will work closely with our partner AstraZeneca to investigate the cause of this incident and the overall plans for the AZD2820 program," said Palatin's Chief Executive Carl Spana. AstraZeneca, which is the U.K.'s second-biggest drug company, remains committed to collaborating with Palatin on the continued development of obesity treatments, Dr. Spana said. The Phase I study of AZD2820 had enrolled 72 obese but otherwise healthy men for a placebo-controlled trial. Eleven of them had completed their dosing regimen before the trial was halted. The study had been assessing the safety, tolerability and other effects of AZD2820. Another study of the same drug was completed in 2011 without any reported serious adverse events. Under the terms of the collaboration with AstraZeneca, Palatin is eligible for milestone payments upon reaching certain developments, in addition to royalties on sales. AstraZeneca has responsibility for the drug's commercialization, and discovery and development costs. Palatin shares closed at 52 cents on Monday and were inactive premarket. The stock is up 28% so far this year. AstraZeneca's American depositary shares were up 1.4% to $42.75 in premarket trading. Through Monday's close, the equity was down 8.9% so far this year. Write to Kristin Jones at

Stock News for Palatin (PTN)
05/17/201609:02:41Current Report Filing (8-k)
05/17/201607:30:00Palatin Technologies, Inc. Reports Third Quarter Fiscal Year...
05/16/201616:50:51Quarterly Report (10-q)
05/12/201607:30:00Palatin Technologies, Inc. to Report Third Quarter Fiscal Year...
04/22/201616:19:06Additional Proxy Soliciting Materials (definitive) (defa14a)
04/22/201616:19:06Proxy Statement (definitive) (def 14a)
02/26/201607:30:00Palatin Technologies Presents Bremelanotide Alcohol Interaction...
02/16/201615:55:38Amended Statement of Ownership (sc 13g/a)
02/16/201608:31:57Current Report Filing (8-k)
02/16/201607:30:00Palatin Technologies, Inc. Reports Second Quarter Fiscal Year...
02/12/201616:35:39Quarterly Report (10-q)
02/10/201607:30:00Palatin Technologies, Inc. to Report Second Quarter Fiscal Year...
02/08/201607:30:00Palatin Technologies Strengthens Intellectual Property Surrounding...
02/04/201607:30:00Palatin Technologies To Present At The BIO CEO & Investor Conference
12/11/201516:27:42Current Report Filing (8-k)
12/10/201516:48:17Statement of Changes in Beneficial Ownership (4)
12/10/201516:46:33Statement of Changes in Beneficial Ownership (4)
12/10/201516:46:04Statement of Changes in Beneficial Ownership (4)
12/10/201516:44:29Statement of Changes in Beneficial Ownership (4)
12/10/201516:43:47Statement of Changes in Beneficial Ownership (4)

Palatin Tech and other American Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations